Barclays
INBX icon

Barclays’s Inhibrx INBX Stock Holding History

Barclays’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
2,347
+680
+41% +$68.1K ﹤0.01% 3633
2026
Q1 		$112K Sell
1,667
-20,212
-92% -$1.5M ﹤0.01% 3977
2025
Q4 		$1.73M Buy
21,879
+8,411
+62% +$573K ﹤0.01% 3045
2025
Q3 		$454K Sell
13,468
-3,696
-22% -$91K ﹤0.01% 3867
2025
Q2 		$245K Buy
17,164
+3,881
+29% +$50.2K ﹤0.01% 4157
2025
Q1 		$186K Sell
13,283
-5,558
-29% -$75.5K ﹤0.01% 4086
2024
Q4 		$290K Buy
18,841
+2,786
+17% +$42.4K ﹤0.01% 4136
2024
Q3 		$251K Buy
16,055
+12,476
+349% +$175K ﹤0.01% 4182
2024
Q2 		$50.7K Buy
+3,579
New +$55.9K ﹤0.01% 4210

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's INBX Position: Q2 2026 in Review

Barclays increased its Inhibrx (INBX) stake by 41% in Q2 2026, buying an estimated $68.1K and bringing the position to 2,347 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3633.

Barclays first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.73M in Q4 2025. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Barclays held 2,347 shares of Inhibrx worth $222K as of Q2 2026.
  • Barclays bought 680 Inhibrx shares in Q2 2026, an estimated $68.1K.
  • Inhibrx made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3633 holding.
  • Barclays first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • Barclays's Inhibrx position peaked at $1.73M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.